Key Drivers
- Earnings Deterioration
- Liquidity Pressure
- High Leverage
AIAI Summary
Teva's investment case has shifted from distressed generics to a cash-generative branded-pharma turnaround, but upside requires Austedo, Ajovy, UZEDY and cost savings to outpace legacy erosion and convert $2.3–$2.5B annual operating cash flow into sustained deleveraging and margins. Investors should view it as an execution-driven hold/buy opportunity, closely monitoring branded growth and free cash flow given $17B of debt and fragile reported earnings.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Earnings Deterioration
- •Liquidity Pressure
- •High Leverage
TEVA's strong 2025 profitability and cash flow are being overshadowed by a weak latest quarter, deteriorating liquidity, high leverage, and elevated valuation risk.
Price Behavior
Key Price Behavior Insights:
- •Constructive advance
- •Key breakout
- •Volatile pullbacks
TEVA gained 5.9% over the last month and remains bullish above its average, but traders should watch for a breakout above $39.25 or downside risk below $38.50.
Volatile advance from the $36 area into the $39 area
Sentiment & News
Key News Insights:
- •Credit upgrade
- •Pipeline progress
- •Debt refinancing
Teva's growth strategy gains traction through pipeline progress, debt refinancing, credit upgrades, and portfolio expansion, though acquisition and pricing-policy risks remain.
The developments strengthen Teva's financial and growth outlook, supporting a constructive view on the shares
Similar Companies in Healthcare
Other companies in the same sector with AI ratings